Study endpoints
SECONDARY
The primary endpoint of the SAD/MAD Study 1 was to evaluate the safety and tolerability of single and multiple doses of lumicitabine as determined by AEs, physical examinations, vital signs, 12-lead electrocardiograms, and clinical laboratory results, including serum chemistry and hematological findings. In Study 2, the primary endpoint was RSV ribonucleic acid (RNA) logOther secondary endpoints included the evaluation of PK parameters of lumicitabine metabolites (ALS-008112, ALS-008144) in blood. PK assessments included the maximum observed concentration (C